



(86) Date de dépôt PCT/PCT Filing Date: 2003/11/26
(87) Date publication PCT/PCT Publication Date: 2004/06/10
(85) Entrée phase nationale/National Entry: 2005/04/22
(86) N° demande PCT/PCT Application No.: EP 2003/013320
(87) N° publication PCT/PCT Publication No.: 2004/048472
(30) Priorités/Priorities: 2002/11/27 (60/429,719) US;
2003/10/17 (60/512,591) US

(51) Cl.Int.⁷/Int.Cl.⁷ C08K 5/09, A61L 31/00, A61L 27/00,
C08K 5/00

(71) Demandeur/Applicant:
NOVARTIS AG, CH

(72) Inventeurs/Inventors:
DEVLIN, BRIAN GERRARD, US;
MEDINA, ARTURO NORBERTO, US;
SENTELL, KAREN BELINDA, US;
PERREAULT, STEPHEN RAYMOND, US;
TENA, MIREILLE, US

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : STABILISATION DE MATERIAUX POLYMERES CONTENANT DU POLY(OXYALKYLENE)
(54) Title: STABILIZATION OF POLY(OXYALKYLENE) CONTINING POLYMERIC MATERIALS

(57) **Abrégé/Abstract:**

The present invention provides a method for producing a medical device, preferably an ophthalmic device, more preferably a contact lens, made of a stabilized poly(oxyalkylene)containing polymeric material. The method of the invention comprises the steps of: curing, in a mold, a composition comprising (a) a prepolymer having at least one poly(oxyalkylene) unit, (b) a biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymer made from the composition, (c) optionally a photoinitiator or a thermal initiator, and (d) optionally one or more vinylic monomers, to form the medical device being less susceptible to oxidative degradation; and removing the medical device from the mold.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/048472 A3

(51) International Patent Classification⁷: **C08K 5/09**,
A61L 27/00, C08K 5/00, A61L 31/00

Raymond [US/US]; 4339 Canoe Court, Norcross, GA 30092 (US). **TENA, Mireille** [CH/US]; The Concorde, #501, 2870 Pharr Court South, Atlanta, GA 30305 (US).

(21) International Application Number:
PCT/EP2003/013320

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date:
26 November 2003 (26.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/429,719 27 November 2002 (27.11.2002) US
60/512,591 17 October 2003 (17.10.2003) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DEVLIN, Brian, Gerrard** [GB/US]; 3686 Castle View Court, Suwanne, GA 30024 (US). **MEDINA, Arturo, Norberto** [US/US]; 2951 Satellite Blvd. #513, Duluth, GA 30096 (US). **SENTELL, Karen, Belinda** [US/US]; 10610 Timberstone Road, Alpharetta, GA 30202 (US). **PERREAULT, Stephen**,

(88) Date of publication of the international search report:
15 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABILIZATION OF POLY(OXYALKYLENE) CONTAINING POLYMERIC MATERIALS

(57) Abstract: The present invention provides a method for producing a medical device, preferably an ophthalmic device, more preferably a contact lens, made of a stabilized poly(oxyalkylene)containing polymeric material. The method of the invention comprises the steps of: curing, in a mold, a composition comprising (a) a prepolymer having at least one poly(oxyalkylene) unit, (b) a biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymer made from the composition, (c) optionally a photoinitiator or a thermal initiator, and (d) optionally one or more vinylic monomers, to form the medical device being less susceptible to oxidative degradation; and removing the medical device from the mold.



WO 2004/048472 A3

Stabilization of poly(oxyalkylene) containing polymeric materials

The present invention relates to stabilization of poly(oxyalkylene)-containing polymeric materials. More specifically, the present invention relates to a method for stabilizing a poly(oxyalkylene)-containing polymeric material; a method for making a medical device, preferably an ophthalmic device, containing a stabilized poly(oxyalkylene)-containing polymeric material; a method for sterilizing a medical device having a core and/or a coating made of a poly(oxyalkylene)-containing polymeric material, wherein the method is characterized by having an improved stability of the poly(oxyalkylene)-containing polymeric material. In addition, the present invention relates to a stabilized poly(oxyalkylene)-containing polymeric material; a medical device comprising a core or a coating made of a stabilized poly(oxyalkylene)-containing polymeric material; and a solution for sterilizing and/or storing a medical device having a core or a coating made of a poly(oxyalkylene)-containing polymeric material, wherein the solution is capable of stabilizing the poly(oxyalkylene)-containing polymeric material.

BACKGROUND OF THE INVENTION

Because of the biocompatibility of poly(alkyleneglycols), also known as polyalkyl ethers or poly(alkylene oxide), poly(oxyalkylene)-containing polymers can find use in various fields, in particular in biomedical fields, such as, for example, carriers for drug-delivery, artificial tissues, dentifrices, contact lenses, intraocular lenses, and other biomedical devices. (For a recent review of applications see the ACS Symposium Series 680, "Poly(ethyleneglycol): Chemistry and Biological Applications", 1997, Harris and Zalipsky, eds.) However, poly(oxyalkylene)-containing polymers may be susceptible to degradation, in particular, oxidative degradation of its poly(oxyalkylene) chains under aerobic conditions. Oxidative degradation may cause changes in the properties of an article made from the poly(oxyalkylene)-containing polymers and limit the applications of poly(oxyalkylene)-containing polymers.

Susceptibility to oxidative degradation of a poly(oxyalkylene)-containing polymer can be effected by the method used in preparation and purification, post-manufacturing process (e.g., sterilization with autoclave, or the like), storage, and use. It is generally believed that, under aerobic conditions, a poly(oxyalkylene)-containing polymer may be degraded

- 2 -

according to the mechanism of a free-radical chain reaction involving an oxidation step (see "Stability of the Polyoxyethylene Chain", Donbrow, Max. Surfactant Sci. Ser. (1987), 23 (Nonionic Surfactants), 1011-1072, and references contained therein). First, homolytic degradation of the alkylene glycol chain in a poly(oxyalkylene)-containing polymer is initiated photochemically, thermally, or chemically (e.g., by actinic radiation including UV radiation, ionizing radiation, or microwave, at elevated temperatures, or with free-radical initiators, etc.), producing an alkylene glycol radical. This radical undergoes spontaneous oxidation under aerobic conditions to form peroxides and hydroperoxides. The resulting peroxides and hydroperoxides may then undergo a variety of subsequent reactions to yield by-products such as formic acid, lower alcohols, and the like. For a contact lens made from a poly(oxyalkylene)-containing polymer, the poly(oxyalkylene) chain of the poly(oxyalkylene)-containing polymer may be susceptible to oxidative degradation, leading to formation of by-products such as formic acid and others. These by-products, especially formic acid which can have irritating effects, are not desirable, and thus need to be eliminated or minimized. Moreover, a medical device made from a poly(oxyalkylene)-containing polymer may have a shorter shelf life because of oxidative degradation of the poly(oxyalkylene)-containing polymer.

There have been attempts to stabilize poly(oxyalkylene)-containing materials used for medical devices by using antioxidants. For example, see U.S. Patent Nos. 5,290,585, 5,160,790, 5,179,186, 5,367,001, 4,886,866 and 5,175,229, and EP 0 333 899 B1. The antioxidants disclosed in those patents are hindered phenolic compounds, such as butylated hydroxytoluene, tris (3,5-di-t-butyl-4-hydroxy benzyl) isocyanurate, 2,2'-methylenebis (4-methyl-6-t-butyl phenol), 1,3,5-Trimethyl-2,4,6-tris (3,5-di-t-butyl-4-hydroxybenzyl) benzene, octadecyl 3,5, di-t-butyl-4-hydroxyhydrocinnamate, 4,4 methylenebis (2,6-di-t-butylphenol), p,p - dioctyl diphenylamine, 1,1,3-tris-(2-methyl-4-hydroxy-5-t-butylphenyl) butane, Irganox (Ciba Geigy), and Santonox (Monsanto Corp.). However, there are some disadvantages associated with those antioxidants in the prior art for stabilizing poly(oxyalkylene)-containing materials. Those antioxidants may not be suitable for applications where the device is remain in contact with living tissues for long periods of times due to their cytotoxicity, or are water insoluble so that they can not be used in a water-base formulation for making the poly(oxyalkylene)-containing materials. Furthermore, those antioxidants may not be efficient in stabilizing poly(oxyalkylene)-containing materials and/or reducing the levels of by-products

such as formic acid, in case where the poly(oxyalkylene)-containing materials are used to make contact lenses or other medical devices.

Accordingly, there is still a need for a method for stabilizing poly(oxyalkylene)-containing polymeric materials using a biocompatible material. Such stabilized poly(oxyalkylene)-containing polymeric materials can find particular use in making a medical device which are in contact with living cells or tissues.

SUMMARY OF THE INVENTION

One object of the invention is to provide a method for stabilizing a poly(oxyalkylene)-containing polymeric material using one or more biocompatible materials.

Another object of the invention is to provide a method for producing a stabilized poly(oxyalkylene)-containing polymeric material.


Still another object of the invention is to provide a method or a composition for making a medical device from a stabilized poly(oxyalkylene)-containing polymeric material.

A further object of the invention is to provide a stabilized poly(oxyalkylene)-containing polymeric material and a medical device made from a stabilized poly(oxyalkylene)-containing polymeric material.

A still further object of the invention is to provide a method for sterilizing a medical device made of a poly(oxyalkylene)-containing polymeric material while improving the stability of the poly(oxyalkylene)-containing polymeric material.

These and other objects of the invention are met by the various aspects of the invention described herein.


In accomplishing the foregoing, there is provided, in accordance with one aspect of the present invention, a stabilized poly(oxyalkylene)-containing polymeric material, which comprises: (a) a polymer network having at least one unit of formula (I)



- 4 -

wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_6 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100; and (b) a biocompatible organic multi-acid or biocompatible salt thereof present in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material, wherein the biocompatible organic multi-acid or biocompatible salt thereof is distributed within the polymeric material but not crosslinked to the polymer network. Preferably, the biocompatible organic multi-acid or biocompatible salt thereof is present in an amount effective to impart to the medical device a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

In another aspect, the present invention provides a medical device comprising: a poly(oxyalkylene)-containing polymeric material and a biocompatible organic multi-acid or biocompatible salt thereof, wherein the poly(oxyalkylene)-containing polymeric material has a polymer network having at least one unit of formula (I)



wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_4 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100; wherein the biocompatible organic multi-acid or biocompatible salt thereof is distributed within the poly(oxyalkylene)-containing polymeric material but not crosslinked to the polymer network, and wherein the biocompatible organic multi-acid or biocompatible salt thereof is present in an amount effective to improve the stability of the medical device so that the medical device has a decreased susceptibility to oxidative degradation, characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

In still another aspect, the present invention provides a method for producing a medical device, preferably an ophthalmic device, more preferably a contact lens, made of a stabilized poly(oxyalkylene)-containing polymeric material, the method comprising the steps of: (1) obtaining a polymerizable fluid composition comprising (a) a prepolymer having at least one poly(oxyalkylene) unit of formula (I) and ethylenically unsaturated groups, (b) a biocompatible organic multi-acid or biocompatible salt thereof, (c) optionally a photoinitiator or a thermal initiator, and (d) optionally one or more vinylic monomers; (2) introducing an

- 5 -

amount of the polymerizable fluid composition in a mold for making the medical device; and (3) actinically or thermally polymerizing the polymerizable fluid composition in the mold to form the medical device having a polymer network having at least one unit of formula (I) and the biocompatible organic multi-acid or biocompatible salt thereof which is not crosslinked to the polymer network, wherein the biocompatible organic multi-acid or biocompatible salt thereof is present in an amount effective to improve the stability of the medical device so that the medical device has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

In a further aspect, the present invention provides a method for producing a medical device, preferably an ophthalmic device, more preferably a contact lens, made of a stabilized poly(oxyalkylene)-containing polymeric material, the method comprising the steps of: (1) introducing a reactive mixture into a mold for making the medical device by using a Reaction Injection Molding (RIM) process to form the medical device, wherein the reactive mixture comprises (a) at least one monomer or prepolymer having at least one poly(oxyalkylene) unit of formula (I) and functional groups which are amino, carboxy, hydroxyl or isocyanato groups and (b) at least one of an organic diamine, an organic polyamine, an organic diacid, an organic polyacid, an organic diol, an organic polyol, an organic diisocyanate, and organic polyisocyanate, provided that components (a) and (b) react with each other to form a polyurea and/or polyurethane network; (2) removing the medical device from the mold; and (3) impregnating the medical device with a biocompatible organic multi-acid or biocompatible salt thereof in an amount effective to improve the stability of the medical device so that the medical device has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

In another further aspect, the present invention provides a method for sterilizing a medical device which comprises a core material and/or a coating, wherein the core material and the coating, independently from each other, are made of a poly(oxyalkylene)-containing polymeric material, the method comprising: autoclaving the medical device in an aqueous solution containing a biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material, so that the poly(oxyalkylene)-containing polymeric material has a decreased

- 6 -

susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

In still a further aspect, the present invention provides an aqueous solution for sterilizing and/or storing an ophthalmic device, wherein the ophthalmic device is made of a poly(oxyalkylene)-containing polymeric material, the aqueous solution having: a biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material; an osmolarity of about 200 to 450 milli-osmole in 1000 ml (unit: mOsm/ml), wherein the aqueous solution is capable of improving the stability of the poly(oxyalkylene)-containing polymeric material, so that the poly(oxyalkylene)-containing polymeric material has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

These and other aspects of the invention will become apparent from the following description of the preferred embodiments. As would be obvious to one skilled in the art, many variations and modifications of the invention may be effected without departing from the spirit and scope of the novel concepts of the disclosure.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Reference now will be made in detail to the embodiments of the invention. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment. Thus, it is intended that the present invention cover such modifications and variations as come within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present invention are disclosed in or are obvious from the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not intended as limiting the broader aspects of the present invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention

- 7 -

belongs. Generally, the nomenclature used herein and the laboratory procedures are well known and commonly employed in the art. Conventional methods are used for these procedures, such as those provided in the art and various general references. Where a term is provided in the singular, the inventors also contemplate the plural of that term. The nomenclature used herein and the laboratory procedures described below are those well known and commonly employed in the art.

An "article" refers to a medical device or a mold for making a medical device.

A "medical device", as used herein, refers to a device or a part thereof having one or more surfaces that contact tissue, blood, or other bodily fluids of patients in the course of their operation or utility. Exemplary medical devices include: (1) extracorporeal devices for use in surgery such as blood oxygenators, blood pumps, blood sensors, tubing used to carry blood and the like which contact blood which is then returned to the patient; (2) prostheses implanted in a human or animal body such as vascular grafts, stents, pacemaker leads, heart valves, and the like that are implanted in blood vessels or in the heart; (3) devices for temporary intravascular use such as catheters, guide wires, and the like which are placed into blood vessels or the heart for purposes of monitoring or repair; (4) artificial tissues such as artificial skin for burn patients; (5) dentifrices, dental moldings; (6) ophthalmic devices. In a preferred embodiment, medical devices are ophthalmic devices; and (7) cases or containers for storing ophthalmic devices or ophthalmic solutions.

An "ophthalmic device", as used herein, refers to a contact lens (hard or soft), an intraocular lens, a corneal onlay, other ophthalmic devices (e.g., stents, or the like) used on or about the eye or ocular vicinity.

"Biocompatible", as used herein, refers to a material or surface of a material, which may be in intimate contact with tissue, blood, or other bodily fluids of a patient for an extended period of time without significantly damaging the ocular environment and without significant user discomfort.

"Ophthalmically compatible", as used herein, refers to a material or surface of a material which may be in intimate contact with the ocular environment for an extended period of time without significantly damaging the ocular environment and without significant user

- 8 -

discomfort. Thus, an ophthalmically compatible contact lens will not produce significant corneal swelling, will adequately move on the eye with blinking to promote adequate tear exchange, will not have substantial amounts of protein or lipid adsorption, and will not cause substantial wearer discomfort during the prescribed period of wear.

"Ocular environment", as used herein, refers to ocular fluids (e.g., tear fluid) and ocular tissue (e.g., the cornea) which may come into intimate contact with a contact lens used for vision correction, drug delivery, wound healing, eye color modification, or other ophthalmic applications.

A "monomer" means a low molecular weight compound that can be polymerized. Low molecular weight typically means average molecular weights less than 700 Daltons.

A "vinyl monomer", as used herein, refers to a low molecular weight compound that has an ethylenically unsaturated group and can be polymerized actinically or thermally. Low molecular weight typically means average molecular weights less than 700 Daltons. Exemplary ethylenically unsaturated groups include without limitation acryloyl, methacryloyl, allyl, vinyl, styrenyl, or other C=C containing groups.

A "hydrophilic vinyl monomer", as used herein, refers to a vinyl monomer which as a homopolymer typically yields a polymer that is water-soluble or can absorb at least 10 percent by weight water.

A "hydrophobic vinyl monomer", as used herein, refers to a vinyl monomer which as a homopolymer typically yields a polymer that is insoluble in water and can absorb less than 10 percent by weight water.

A "macromer" refers to a medium and high molecular weight compound or polymer that contains functional groups capable of undergoing further polymerizing/crosslinking reactions. Medium and high molecular weight typically means average molecular weights greater than 700 Daltons. Preferably, a macromer contains ethylenically unsaturated groups and can be polymerized actinically or thermally.

A "polymer" means a material formed by polymerizing/crosslinking one or more monomers.

- 9 -

A "prepolymer" refers to a starting polymer which can be cured (e.g., crosslinked and/or polymerized) actinically or thermally or chemically to obtain a crosslinked and/or polymerized polymer having a molecular weight much higher than the starting polymer. Preferably, a prepolymer contains ethylenically unsaturated groups and can be polymerized actinically or thermally.

As used herein, "actinically" in reference to curing or polymerizing of a polymerizable composition or material means that the curing (e.g., crosslinked and/or polymerized) is performed by actinic irradiation, such as, for example, UV irradiation, ionized radiation (e.g. gamma ray or X-ray irradiation), and microwave irradiation.

A "photoinitiator" refers to a chemical that initiates radical crosslinking/polymerizing reaction by the use of light. Suitable photoinitiators include, without limitation, benzoin methyl ether, diethoxyacetophenone, a benzoylphosphine oxide, 1-hydroxycyclohexyl phenyl ketone, Darocure[®] types, and Irgacure[®] types, preferably Darocure[®] 1173, and Irgacure[®] 2959.

A "thermal initiator" refers to a chemical that initiates radical crosslinking/polymerizing reaction by the use of heat energy. Examples of suitable thermal initiators include, but are not limited to, 2,2'-azobis (2,4-dimethylpentanenitrile), 2,2'-azobis (2-methylpropanenitrile), 2,2'-azobis (2-methylbutanenitrile), peroxides such as benzoyl peroxide, and the like. Preferably, the thermal initiator is azobisisobutyronitrile (AIBN).

A "stabilized poly(oxyalkylene)-containing polymeric material" means that a poly(oxyalkylene)-containing polymeric material, which is prepared from a composition comprising a stabilizer and/or subjected to a sterilization treatment in a solution containing the stabilizer, is less susceptible to oxidative degradation (i.e., characterized by the amount of detectable formic acid and optionally other degradation by-products in a stabilized poly(oxyalkylene)-containing polymeric material being 80 % or less, preferably 65 % or less, more preferably 50 % or less, of that detected in a non-stabilized poly(oxyalkylene)-containing polymeric material). A "non-stabilized poly(oxyalkylene)-containing polymeric material" means that a poly(oxyalkylene)-containing polymeric material, which is prepared from a composition without the stabilizer and/or subjected to a sterilization treatment in a solution without the stabilizer.

- 10 -

“Improve the stability of a poly(oxyalkylene)-containing polymeric material” means that the susceptibility to oxidative degradation of a poly(oxyalkylene)-containing polymeric material, which is prepared from a composition comprising a stabilizer and/or subjected to a sterilization treatment in a solution containing the stabilizer, is reduced (characterized by the amount of detectable formic acid and optionally other degradation by-products in a stabilized poly(oxyalkylene)-containing polymeric material being smaller than that detected in a non-stabilized corresponding poly(oxyalkylene)-containing polymeric material). The amount of detectable formic acid and optionally other degradation by-products derived from oxidative degradation of a poly(oxyalkylene)-containing polymeric material can be determined by any known suitable methods, such as, for example, ion-exchange chromatography described in Examples.

A “decreased susceptibility to oxidative degradation” in reference to a poly(oxyalkylene)-containing polymeric material or a medical device comprising a poly(oxyalkylene)-containing polymeric material means that its susceptibility to oxidative degradation is decreased by having a stabilizer therein. Typically, a decreased susceptibility to oxidative degradation of a poly(oxyalkylene)-containing polymeric material or a medical device comprising a poly(oxyalkylene)-containing polymeric material is characterized by having a stabilizer-induced reduction (preferably at least an 1.5-fold reduction, more preferably at least a 3-fold reduction, even more preferably at least a 5-fold reduction, most preferably at least a 10-fold reduction) of the amount of detectable formic acid and optionally other degradation by-products derived from oxidative degradation of the poly(oxyalkylene)-containing polymeric material. An “X-fold reduction of the amount of detectable formic acid and optionally other degradation by-products” means that, when comparing a stabilized poly(oxyalkylene)-containing polymeric material (or a stabilized medical device containing a stabilizer) with a corresponding non-stabilized poly(oxyalkylene)-containing polymeric material (or a non-stabilized medical device without a stabilizer), the amount of detectable formic acid and optionally other degradation by-products in the non-stabilized poly(oxyalkylene)-containing polymeric material (or the non-stabilized medical device) is at least X folds of the amount of detectable formic acid and optionally other degradation by-products in the stabilized poly(oxyalkylene)-containing polymeric material (or the stabilized medical device).


An “interpenetrating polymer network (IPN)” as used herein refers broadly to an intimate network of two or more polymers at least one of which is either synthesized and/or

- 11 -

crosslinked in the presence of the other(s). Techniques for preparing IPN are known to one skilled in the art. For a general procedure, see U.S. Patent Nos. 4,536,554, 4,983,702, 5,087,392, and 5,656,210. The polymerization is generally carried out at temperatures ranging from about room temperature to about 145 °C.

The present invention generally relates to a stabilized poly(oxyalkylene)-containing polymeric material and methods for making the same.

In one aspect, the present invention provides a stabilized poly(oxyalkylene)-containing polymeric material. A stabilized poly(oxyalkylene)-containing polymeric material of the invention comprises: (a) a polymer network having at least one unit of formula (I)



wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_6 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100; and (b) a biocompatible organic multi-acid or biocompatible salt thereof present in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material, which is distributed within the polymeric material but not crosslinked to the polymer network.

In accordance with the present invention, a poly(oxyalkylene)-containing polymeric material can be any polymer which is a reaction product of a mixture including a poly(oxyalkylene) polymer with functional groups (e.g., amino, hydroxyl, acid, or isocyanato groups) and at least a chemical with functional groups (e.g., amino, hydroxyl, isocyanato, or acid groups) which are co-reactive with the functional groups of poly(oxyalkylene) polymer. Examples of such polymer include without limitation: (1) a polyester obtained by esterification of the terminal diols of a hydroxy terminated (diols) poly(oxyalkylene)-containing polymer with organic monoacids or diacids such as, for example, glutaric or adipic acids; (2) a polyamide obtained by reacting an amine terminated poly(oxyalkylene)-containing polymer with organic monoacids or diacids acids such as, for example, glutaric or adipic acids; (3) a polyurethane which is the copolymerization product of a mixture comprising one or more hydroxyl (or isocyanate)-terminated poly(oxyalkylene)-containing polymer and one or more organic di- or polyisocyanates (or diols or polyols); (4) a polyurea which is the copolymerization product of a mixture comprising one or more amine (or isocyanate)-terminated poly(oxyalkylene)-containing polymer and one or more di- or multi-isocyanates (or diamines or polyamines);

and a polyurea/polyurethane which is the copolymerization product of a mixture comprising one or more amine or hydroxy-terminated poly(oxyalkylene)-containing polymer, one or more di- or multi-isocyanates and one or more organic di- or polyamines (or di- or polyols). The above examples have been given as a means of illustrating the aspects of the invention and are not limiting in any way. It should be understood that a poly(oxyalkylene)-containing polymeric material can also contain one or more silicone and/or fluorine atoms.

In accordance with the present invention, a poly(oxyalkylene)-containing polymeric material can also be an interpenetrating or semi-interpenetrating polymer network. Exemplary interpenetrating polymer networks are interpenetrating polyurea/polyacrylic networks disclosed in EP 0 735 097 B1. Such interpenetrating polyurea/polyacrylic networks are formed by polymerizing a reactive mixture comprising: (a) at least one amine-terminated poly(alkylene glycol); (b) an organic di- or polyisocyanate which reacts with (a) to form a polyurea network; (c) an acrylic ester; (d) a free radical initiator to polymerize (c) to form a polyacrylic network; and (e) a triamine to crosslink (a).

Exemplary poly(alkylene glycol)s include, but are not limited to, a poly(ethylene glycol), a poly(1-propylene glycol), a poly(2-propylene glycol), a poly(ethylene glycol)/ poly(propylene glycol) block polymer, a poly(ethylene glycol) / poly(propylene glycol) / poly(butylene glycol) block polymer, a polytetrahydrofuran, a poloxamer, and the like.

In accordance with the present invention, a stabilized poly(oxyalkylene)-containing polymeric material has a decreased susceptibility to oxidative degradation, characterized by having preferably at least an 1.5-fold reduction of, more preferably at least a 3-fold reduction, even more preferably at least a 5-fold reduction of, most preferably at least 10-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

Any known suitable organic multi-acids or biocompatible salts thereof may be applied, which are water-soluble, non-toxic, biocompatible, and capable of stabilizing poly(oxyalkylene) chains in the presence of UV light or free radical sources or at high temperatures. Exemplary organic multi-acids suitable for the present invention include, but are not limited to, hydroxy diacids, hydroxy multi-acids, amino acids, and the like. Preferably, an organic multi-acid of the present invention is an α -oxo-multi-acid, such as, for example, citric acid, 2-ketoglutaric acid, or malic acid. More preferably, an organic multi-acid is citric or malic acid.

- 13 -

Biocompatible (preferably ophthalmically compatible) salts of organic multi-acids suitable for the present invention include sodium, potassium, and ammonium salts.

As used herein, an "alpha-oxo-multiacid" refers to an acid which has a plurality (two or more) of carboxyl groups and at least one carbon atom which is simultaneously substituted by a carboxyl group and an oxygen atom, i.e., O-C-COOR, wherein the oxygen could be a carbonyl, a hydroxy, an esterified hydroxy, an ether, or the like, and wherein the oxygen is on the carbon which is alpha to the carboxyl group.

In accordance with the present invention, a biocompatible organic multi-acid or biocompatible salt thereof can be introduced into a stabilized poly(oxyalkylene)-containing polymeric material either by adding it into a pre-polymerization composition for making the poly(oxyalkylene)-containing polymeric material and/or by immersing a poly(oxyalkylene)-containing polymeric material in a solution containing the biocompatible organic multi-acid or biocompatible salt thereof (i.e., impregnation of the poly(oxyalkylene)-containing polymeric material with the biocompatible organic multi-acid or biocompatible salt thereof).

The concentration of a biocompatible organic multi-acid or biocompatible salt thereof in a pre-polymerization composition for making a stabilized poly(oxyalkylene)-containing polymeric material or in a solution for impregnation of the poly(oxyalkylene)-containing polymeric material with the biocompatible organic multi-acid or biocompatible salt thereof is preferably from 0.001 millimolar to the solubility limit of a particular biocompatible organic multi-acid or biocompatible salt thereof, more preferentially from 10 to 300 millimolar. It is understood that the weight percentages will change based on the molecular weight of the acid employed.

In a preferred embodiment, a stabilized poly(oxyalkylene)-containing polymeric material of the invention is a copolymerization product of a composition comprising:

(a) a prepolymer containing ethylenically unsaturated groups and at least one unit of formula

$$-O-(R_1-O)_n-(R_2-O)_m-(R_3-O)_p- \quad (I)$$

wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_4 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100;

- 14 -

- (b) a water-soluble and biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material made from the composition;
- (c) optionally a photoinitiator or a thermal initiator; and
- (d) optionally one or more vinylic monomers.

In another preferred embodiment, a stabilized poly(oxyalkylene)-containing polymeric material of the invention is a poly(oxyalkylene)-containing polymeric material impregnated with a biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material, wherein the poly(oxyalkylene)-containing polymeric material is a copolymerization product of a composition comprising:

- (a) a prepolymer containing ethylenically unsaturated groups and at least one unit of formula
- $$-O-(R_1-O)_n-(R_2-O)_m-(R_3-O)_p- \quad (I)$$

wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_4 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100;

- (b) optionally a photoinitiator or a thermal initiator; and
- (c) optionally one or more vinylic monomers.

Impregnation of a poly(oxyalkylene)-containing polymeric material can be performed according to any known suitable methods, for example, such as immersing the poly(oxyalkylene)-containing polymeric material in a solution containing a biocompatible organic multi-acid or biocompatible salt thereof.

A prepolymer having at least one unit of formula (I) and ethylenically unsaturated groups can be prepared according to any methods known to a person skilled in the art. For example, ethylenically unsaturated groups, such as, for example, acryloyl, methacryloyl, allyl, vinyl, styrenyl, or other $C=C$ containing groups, could be covalently attached to the poly(alkylene glycol) moiety according to any method known to a person skilled in the art.

One example of such prepolymer is a crosslinkable polyurea polymer described in U.S. patent No. 6,479,587. Such crosslinkable polyurea polymer can be prepared by introducing ethylenically unsaturated groups into a polyurea which is the copolymerization product of a

reaction mixture including at least one amine-terminated poly(alkylene glycol) and an organic di- or polyisocyanate.

The vinylic monomer which may be additionally used for photo-crosslinking in accordance with the invention may be hydrophilic, hydrophobic or may be a mixture of a hydrophobic and a hydrophilic vinylic monomer. Suitable vinylic monomers include especially those normally used for the manufacture of contact lenses.

It is preferable to use a hydrophobic vinylic monomer, or a mixture of a hydrophobic vinylic monomer with a hydrophilic vinylic monomer, whereby this mixture contains at least 50 percent by weight of a hydrophobic vinyl monomer. In this way, the mechanical properties of the polymer may be improved without the water content dropping substantially. Both conventional hydrophobic vinylic monomers and conventional hydrophilic vinylic monomers are suitable for copolymerization with the radiation-curable prepolymers according to the invention.

Suitable hydrophobic vinylic monomers include, without limitation, C₁-C₁₈-alkylacrylates and -methacrylates, C₃-C₁₈ alkylacrylamides and -methacrylamides, acrylonitrile, methacrylonitrile, vinyl-C₁-C₁₈-alkanoates, C₂-C₁₈-alkenes, C₂-C₁₈-halo-alkenes, styrene, C₁-C₆-alkylstyrene, vinylalkylethers in which the alkyl moiety has 1 to 6 carbon atoms, C₂-C₁₀-perfluoralkyl-acrylates and -methacrylates or correspondingly partially fluorinated acrylates and methacrylates, C₃-C₁₂-perfluoralkyl-ethyl-thiocarbonylaminoethyl-acrylates and -methacrylates, acryloxy and methacryloxy-alkylsiloxanes, N-vinylcarbazole, C₁-C₁₂-alkylesters of maleic acid, fumaric acid, itaconic acid, mesaconic acid and the like. Preference is given e.g. to C₁-C₄-alkylesters of vinylically unsaturated carboxylic acids with 3 to 5 carbon atoms or vinylesters of carboxylic acids with up to 5 carbon atoms.

Examples of suitable hydrophobic vinylic monomers include methylacrylate, ethyl-acrylate, propylacrylate, isopropylacrylate, cyclohexylacrylate, 2-ethylhexylacrylate, methylmethacrylate, ethylmethacrylate, propylmethacrylate, vinyl acetate, vinyl propionate, vinyl butyrate, vinyl valerate, styrene, chloroprene, vinyl chloride, vinylidene chloride, acrylonitrile, 1-butene, butadiene, methacrylonitrile, vinyl toluene, vinyl ethyl ether, perfluorohexylethyl-thio-carbonyl-aminoethyl-methacrylate, isobornyl methacrylate, trifluoroethyl methacrylate, hexafluoro-isopropyl methacrylate, hexafluorobutyl methacrylate,

tris-trimethylsilyloxy-silyl-propyl methacrylate, 3-methacryloxypropyl-pentamethyl-disiloxane and bis(methacryloxypropyl)-tetramethyl-disiloxane.

Suitable hydrophilic vinylic monomers include, without limitation, hydroxy-substituted lower alkylacrylates and -methacrylates, acrylamide, methacrylamide, lower alkyl-acrylamides and -methacrylamides, ethoxylated acrylates and methacrylates, hydroxy-substituted lower alkyl-acrylamides and -methacrylamides, hydroxy-substituted lower alkylvinyl-ethers, sodium ethylene sulphonate, sodium styrene sulphonate, 2-acrylamido-2-methyl-propane-sulphonic acid, N-vinyl pyrrole, N-vinyl succinimide, N-vinyl pyrrolidone, 2- or 4-vinyl pyridine, acrylic acid, methacrylic acid, amino- (whereby the term "amino" also includes quaternary ammonium), mono-lower-alkylamino- or di-lower-alkylamino-lower-alkyl-acrylates and -methacrylates, allyl alcohol and the like. Preference is given e.g. to hydroxy-substituted C₂-C₄-alkyl(meth)acrylates, five- to seven-membered N-vinyl-lactams, N,N-di-C₁-C₄-alkyl-methacrylamides and vinylically unsaturated carboxylic acids with a total of 3 to 5 carbon atoms.

Examples of suitable hydrophilic vinylic monomers include hydroxyethyl methacrylate, hydroxyethyl acrylate, acrylamide, methacrylamide, dimethylacrylamide, allyl alcohol, vinyl pyridine, vinyl pyrrolidone, glycerol methacrylate, N-(1,1-dimethyl-3-oxobutyl)acrylamide, and the like.

Preferred hydrophobic vinylic monomers are methyl methacrylate and vinyl acetate.

Preferred hydrophilic vinylic monomers are 2-hydroxyethyl methacrylate, N-vinyl pyrrolidone and acrylamide.

A photo-initiator or thermal initiator is advantageously added to a composition of the invention. The amount of photo-initiator may be selected from a wide range, whereby an amount of up to 0.05 g/g polymer and especially up to 0.003 g/g polymer has proved favorable.

A composition of the invention can further comprise a color additive which is capable of creating a light colored visibility tint. Such tint can facilitate the handling of ophthalmic lenses. Any known suitable color additives can be used. Preferably, copper phthalocyanin is

- 17 -

used as a color additive which is capable of creating a light blue or light green or other light color visibility tint.

A composition of the invention can optionally comprise other additives, such as, for example, a crosslinking agent, an antimicrobial agents, and/or the like.

Preferably, a composition of the invention is a water-based composition.

Optionally a solvent may be present in a composition of the invention. Any known suitable solvents can be used. Exemplary solvents include, but are not limited to, alcohols, such as lower alkanols, for example ethanol or methanol, and furthermore carboxylic acid amides, such as dimethylformamide, dipolar aprotic solvents, such as dimethyl sulfoxide or methyl ethyl ketone, ketones, for example acetone or cyclohexanone, hydrocarbons, for example toluene, ethers, for example THF, dimethoxyethane or dioxane, and halogenated hydrocarbons, for example trichloroethane, and also mixtures of suitable solvents, for example mixtures of water with an alcohol, for example a water/ethanol or a water/methanol mixture. A person skilled in the art will know how to select a solvent.

A composition of the invention for preparing a stabilized poly(oxyalkylene)-containing polymeric material can find use in making a medical device, preferably an ophthalmic device, more preferably a contact lens.

In another aspect, the present invention provides a method for producing a medical device, preferably an ophthalmic device, more preferably a contact lens, made of a stabilized poly(oxyalkylene)-containing polymeric material, the method comprising the steps of: (1) obtaining a polymerizable fluid composition comprising (a) a prepolymer having at least one poly(oxyalkylene) unit of formula (I) and ethylenically unsaturated groups, (b) a biocompatible organic multi-acid or biocompatible salt thereof, (c) optionally a photoinitiator or a thermal initiator, and (d) optionally one or more vinylic monomers; (2) introducing an amount of the polymerizable fluid composition in a mold for making the medical device; and (3) actinically or thermally polymerizing the polymerizable fluid composition in the mold to form the medical device having a polymer network having at least one unit of formula (I) and the biocompatible organic multi-acid or biocompatible salt thereof which is not crosslinked to the polymer network, wherein the biocompatible organic multi-acid or biocompatible salt

- 18 -

thereof is present in an amount effective to improve the stability of the medical device so that the medical device has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

The polymerizable fluid composition can be introduced into a mold by methods known *per se*, especially conventional dispensing, e.g. dropwise addition in a desired quantity.

Appropriate disposable molds are made, for example, from polypropylene. Suitable materials for re-usable molds are e.g. quartz, sapphire glass or metals.

If the molded articles to be produced are contact lenses, these may be produced in a manner known *per se*, e.g. in a conventional "spin-casting mold", as described for example in U.S. Patent No. 3,408,429, or by the so-called full mold process in a static form, as described e.g. in U.S. Patent Nos. 4,347,198, 5,508,317, 5,583,463, 5,789,464, and 5,849,810.

Crosslinking/polymerizing of the composition may be initiated in the mold actinically (e.g. by means of actinic radiation, such as UV irradiation, gamma or X-ray irradiation) or thermally.

Opening of the mold so that the molded article can be removed from the mold may take place in a manner known *per se*.

If the molded article produced according to the invention is a contact lens which is produced solvent-free from an already purified crosslinkable prepolymer in the absence of vinylic monomers according to the invention, then after removal of the molded article, it is not normally necessary to follow up with purification steps such as extraction. This is because the prepolymers employed do not contain any undesired constituents of low molecular weight; consequently, the crosslinked product is also free or substantially free from such constituents and subsequent extraction can be dispensed with. Accordingly, the contact lens can be directly transformed in the usual way, by hydration, into a ready-to-use contact lens. Appropriate embodiments of hydration are known to the person skilled in the art, whereby ready-to-use contact lenses with very varied water content may be obtained. The contact lens (in particular, a hydrogel contact lens) is expanded, for example, in water, in an

- 19 -

aqueous salt solution, especially an aqueous salt solution having an osmolarity of about 200 to 450 milli-osmole in 1000 ml (unit: mOsm/ml), preferably about 250 to 350 mOsm/l and especially about 300 mOsm/l, or in a mixture of water or an aqueous salt solution with a physiologically compatible polar organic solvent, e.g. glycerol. Preference is given to expansions of the article in water or in aqueous salt solutions.

The aqueous salt solutions used for hydration are advantageously solutions of physiologically compatible salts, such as buffer salts conventionally used in the field of contact lens care, e.g. phosphate salts, or isotonizing agents conventionally used in the field of contact lens care, such as in particular alkali halides, e.g. sodium chloride, or solutions of mixtures thereof. One example of an especially suitable salt solution is an artificial, preferably buffered lachrymal fluid, which is adapted to natural lachrymal fluid as regards pH value and osmolarity, e.g. an unbuffered or preferably buffered common salt solution, for example buffered by phosphate buffer, whose osmolarity and pH value correspond to the osmolarity and pH value of human lachrymal fluid.

The aqueous salt solutions used for hydration preferably contain biocompatible organic multi-acids or biocompatible salts thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymer made from the composition.

The above-defined hydration fluids are preferably at least substantially free from undesired constituents. This is most preferably pure water or an artificial lachrymal fluid as described above.

If the molded article produced according to the invention is a contact lens which is produced from an aqueous solution of an already purified crosslinkable prepolymer in the absence of vinylic monomers according to the invention, then the crosslinked product is likely not to contain any impurities. It is therefore not necessary to carry out subsequent extraction. Since crosslinking is carried out in an essentially aqueous solution, it is additionally unnecessary to carry out subsequent hydration. The contact lenses obtained by this process are therefore notable, according to an advantageous embodiment, for the fact that they are suitable for their intended usage without extraction. By intended usage is understood, in this context, that the contact lenses can be used in the human eye.

The contact lenses obtained according to the invention have a low susceptibility to oxidative degradation, characterized by having a reduced amount of formic acid and/or other degradation by-products detected in the contact lenses. They may have a longer shelf life. Moreover, because of reduction in the formation of formic acid, the contact lenses obtained according to the invention may not cause irritation to the eyes of a wearer.

Of course, all the above-mentioned advantages apply not only to contact lenses, but also to other molded articles according to the invention, for example, an implantable medical device obtained according to the invention. The total of the different advantageous aspects during production of the molded articles according to the invention leads to the suitability of the molded articles in particular as mass-produced articles, for example, as contact lenses which are for daily use and/or for weekly use.


In still another aspect, the present invention provides a method for producing a medical device, preferably an ophthalmic device, more preferably a contact lens, made of a stabilized poly(oxyalkylene)-containing polymeric material, the method comprising the steps of: (1) introducing a reactive mixture into a mold for making the medical device by using a Reaction Injection Molding (RIM) process to form the medical device, wherein the reactive mixture comprises (a) a monomer or prepolymer having at least one poly(oxyalkylene) unit of formula (I) and functional groups which are amino, carboxy, hydroxyl or isocyanato groups and (b) an organic diamine, an organic polyamine, an organic diacid, an organic polyacid, an organic diol, an organic polyol, an organic diisocyanate, or organic polyisocyanate, provided that components (a) and (b) react with each other to form a polyurea and/or polyurethane network; (2) removing the medical device from the mold; and (3) impregnating the medical device with a biocompatible organic multi-acid or biocompatible salt thereof in an amount effective to improve the stability of the medical device so that the medical device has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

The RIM process is a known molding process wherein two or more streams of monomers react in the mold to form a polymer; and is well described by L. T. Manzione in *The Encyclopedia of Polymer Science and Engineering*; 2nd Edition Vol 14, pg. 72.

- 21 -

In a preferred embodiment, the reactive mixture can further comprise one or more prepolymers having ethylenically unsaturated groups or one or more vinylic monomers to form a different polymer network which interpenetrate with the polyurea and/or polyurethane network.

In a further aspect, the present invention provides a medical device comprising a poly(oxyalkylene)-containing polymeric material and a biocompatible organic multi-acid or biocompatible salt thereof present in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material, wherein the poly(oxyalkylene)-containing polymeric material has a polymer network having at least one unit of formula (I)



in which R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_6 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100, and wherein the biocompatible organic multi-acid or biocompatible salt thereof is distributed within the poly(oxyalkylene)-containing polymeric material but not crosslinked to the polymer network. The biocompatible organic multi-acid or biocompatible salt thereof is present in an amount effective to improve the stability of the medical device so that the medical device has a decreased susceptibility to oxidative degradation characterized by having preferably at least an 1.5-fold reduction of, more preferably at least a 3-fold reduction of, even more preferably at least a 5-fold reduction, most preferably at least a 10-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

In a preferred embodiment, the medical device of the invention is a polymerization product of a composition comprising (a) a prepolymer containing ethylenically unsaturated groups and at least one poly(oxyalkylene) unit of formula (I); (b) a water-soluble and biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of a poly(oxyalkylene)-containing polymeric material made from the composition; (c) optionally a photoinitiator or a thermal initiator; and (d) optionally one or more vinylic monomers.

In another preferred embodiment, the biocompatible organic multi-acid or biocompatible salt thereof is impregnated within the poly(oxyalkylene)-containing polymeric material, wherein the poly(oxyalkylene)-containing polymeric material is a polymerization product of a reactive

- 22 -

mixture comprising (a) at least one monomer or prepolymer having at least one poly(oxyalkylene) unit of formula (I) and functional groups which are amino, carboxy, hydroxyl or isocyanato groups, and (b) at least one of an organic diamine, an organic polyamine, an organic diacid, an organic polyacid, an organic diol, an organic polyol, an organic diisocyanate, and organic polyisocyanate, provided that components (a) and (b) react with each other to form a polyurea and/or polyurethane network. More preferably, the reactive mixture further comprises one or more vinylic monomers or prepolymer with ethylenically unsaturated groups. Those monomers or prepolymers can form upon actinical irradiation a different polymer network which interpenetrates the polyurea and/or polyurethane network.

In another further aspect, the present invention provides a method for sterilizing a medical device which comprises a core material and/or a coating, wherein the core material and the coating, independently of each other, are made of a poly(oxyalkylene)-containing polymeric material, the method comprising: autoclaving the medical device in a solution containing a water-soluble and biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material, so that the poly(oxyalkylene)-containing polymeric material has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

A medical device can be coated with a poly(oxyalkylene)-containing material according to any methods known to a person skilled in the art. Exemplary coating techniques include, but are not limited to, dip coating, spraying coating, painting, knife-coating, and printing.

In still a further aspect, the present invention provides an aqueous solution for sterilizing and/or storing an ophthalmic device, wherein the ophthalmic device is made of a poly(oxyalkylene)-containing polymeric material, the aqueous solution having: a biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material; an osmolarity of about 200 to 450 milli-osmole in 1000 ml (unit: mOsm/ml), wherein the aqueous solution is capable of improving the stability of the poly(oxyalkylene)-containing polymeric material, so that the poly(oxyalkylene)-containing polymeric material has a reduced susceptibility to

oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

An aqueous solution of the invention has an osmolarity of, preferably from about 250 to 350 mOsm/l, more preferably about 300 mOsm/l. An aqueous solution of the invention can comprise physiologically compatible salts, such as buffer salts conventionally used in the field of contact lens care, e.g. phosphate salts, or isotonizing agents conventionally used in the field of contact lens care, such as in particular alkali halides, e.g. sodium chloride. An aqueous solution of the invention can further comprise a physiologically compatible polar organic solvent, e.g. glycerol.

The previous disclosure will enable one having ordinary skill in the art to practice the invention. In order to better enable the reader to understand specific embodiments and the advantages thereof, reference to the following non-limiting examples is suggested. However, the following examples should not be read to limit the scope of the invention.

Example 1

68.63 g of Jeffamine XTJ-501 (CAS Registry Number 65605-36-9), 16.04 g of Jeffamine XTJ-502 (CAS Registry Number 65605-36-9, both from Huntsman Corporation), and 2.14 g of diethylene triamine (Aldrich Chemicals) are weighed into a jacketed 1-L reactor. 370 g of tetrahydrofuran (Aldrich) and 200 g of deionized water are added to the reactor and the contents are stirred to dissolve. A sample is taken for titration (0.332 mAeq/g vs. 0.335 by theory). The reactor is then chilled to 0 °C with stirring under nitrogen. 21.74 g of isophorone diisocyanate (Aldrich Chemicals, used as received) is then dissolved in 35 g of THF and added dropwise over 45 minutes. The solution is stirred at temperature for one hour, and then a sample is withdrawn and titrated (0.033 mAeq/g vs. 0.035 theory). 3.5 g of cyclohexylisocyanate (Aldrich Chemicals, used as received) is then added in one portion, and the reactor is stirred at 0 °C for one hour. The product is then decanted to a 2-L flask, and the reactor is chased with 400 mL of water. The combined products are concentrated on a rotary evaporator at 53 °C/80 mBar ultimate vacuum to yield a solution essentially free of tetrahydrofuran. This solution is then ultrafiltered with 20 L of water using a 3-kilodalton membrane. The resulting purified solution is then concentrated to 50% solids on a rotary evaporator.

- 24 -

Example 2

70 g of Poly(ethylene glycol) with a molecular weight of approximately 2000, available from Aldrich Chemicals, is dissolved in 70 g of water.

Example 3

2.00 g of Sodium Ascorbate (Aldrich) is dissolved in 20 g of water. pH was adjusted to 6.92 by addition of 100 µL of 10% Ascorbic acid in water (Aldrich Chemicals). 1.00 g of Irgacure®-2959 (2-Hydroxy-4'-(2-hydroxyethyl)-2-methylpropiophenone, available from Ciba Specialty Chemicals) is mixed with 8.83 g of the ascorbate buffer, and then diluted with 100 g of water. The mixture is dissolved with gentle heating and agitation to provide a clear solution.

Example 4

2.00 g of Sodium Citrate Dihydrate (Aldrich) are dissolved with 20 g of water. pH is adjusted to 7.04 by addition of ~300 µL of sodium dihydrogen citrate (Aldrich Chemicals) which is 10% in water. 1.00 g of Irgacure®-2959 is mixed with 13.11 g of the citrate buffer, and then 100 g of water is added. The mixture is dissolved with gentle heating and agitation to provide a clear solution.

Example 5

2.00 g of sorbitol (Aldrich Chemicals) are dissolved in 20 g of water. 1.00 g of Irgacure®-2959 is mixed with 8.12 g of the sorbitol buffer, and then diluted with 100 g of water. The mixture is dissolved with gentle heating and agitation to provide a clear solution.

Example 6

1.875 g of 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical (hereafter, 4-hydroxy-TEMPO) is diluted to 25 mL with water.

Example 7

1.00 g of Irgacure 2959 (Ciba Specialty Chemicals) is dissolved in 99.00 g of water.

Example 8

10.00g of polymer from Example 2 is mixed with 0.7425 of the solution from Example 7 and diluted with 12.00 g of water to afford a PEG/Irgacure® mixture at a ratio of 100 : 0.15.

Example 9

10.00 g of polymer from Example 2 is mixed with 1.896 g of the solution from Example 7 and diluted with 12.00 g of water to afford a PEG/Irgacure® mixture.

Example 10

10.00 g of polymer from Example 2 is mixed with 1.896 g of the solution from Example 3 and diluted with 12.00 g of water to afford a PEG/Irgacure® mixture amended with ascorbate.

Example 11

10.00 g of polymer from Example 2 is mixed with 1.896 g of the solution from Example 4 and diluted with 12.00 g of water to afford a PEG/Irgacure® mixture amended with citrate.

Example 12

10.00 g of polymer from Example 2 is mixed with 1.8960g of the solution from Example 5 and diluted with 12.00 g of water to afford a PEG/Irgacure® mixture amended with sorbitol.

Example 13

10.00 g of polymer from Example 2 is mixed with 1.8960g of the solution from Example 6 and diluted with 12.00 g of water to afford a PEG/Irgacure® mixture amended with 4-hydroxy-TEMPO.

Example 14

10.00g of polymer from Example 1 is mixed with 0.7425 of the solution from Example 7 and diluted with 12.00 g of water to afford a PEG-Urea/Irgacure® mixture at a ratio of 100 : 0.15.

Example 15

10.00 g of polymer from Example 1 is mixed with 1.896 g of the solution from Example 7 and diluted with 12.00 g of water to afford a PEG-Urea/Irgacure® mixture.

Example 16

10.00 g of polymer from Example 1 is mixed with 1.896 g of the solution from Example 3 and diluted to 12.00 g with water to afford a PEG-Urea/Irgacure® mixture amended with ascorbate.

Example 17

10.00 g of polymer from Example 1 is mixed with 1.8960g of the solution from Example 4 and diluted with 12.00 g of water to afford a PEG-Urea/Irgacure® mixture amended with citrate.

Example 18

10.00 g of polymer from Example 1 is mixed with 1.896 g of the solution from Example 5 and diluted with 12.00 g of water to afford a PEG-Urea/Irgacure® mixture amended with sorbitol.

Example 19

10.00 g of polymer from Example 1 is mixed with 1.896 g of the solution from Example 6 and diluted with 12.00 g of water to afford a PEG-Urea/Irgacure® mixture amended with 4-hydroxy-TEMPO.

Each of the above parent samples from Examples 8 — 19 are then divided into four. Samples with the above example numbers with no suffix(e.g., Example-11) are simply held under refrigeration. Samples with the above lot numbers suffixed with "T" (e.g., Example-11-T) are autoclaved in the dark at 121 °C/30 minutes. Samples with the above lot numbers suffixed with "P" (e.g., Example-11-P) are subjected to 25 minute exposure to UV light. Samples of the above lot numbers suffixed with "PA" (e.g., Example-11-PA) are subjected to 25 minute exposure to UV light, followed by autoclave at 121 °C/30 minutes.

UV light exposure was accomplished using a Macam Lamp with a Phillips HPA 400/30 S Sunlamp bulb. The output of the lamp is captured by an EFOS® Liquid Light Guide and focused on a cylindrical cell quartz cuvette available from Aldrich Chemicals as part number Z27696-0. The cuvette is filled with test substance and placed atop an assembly directly under the liquid light guide. Lamp intensity is ca. 1.8 mW/cm², and exposure time is 25 minutes, implying exposure dose of 2.7 J/cm².

The above-described samples are analyzed by Ion-Exchange Chromatography. The column used is an ICsep ICE-ORH-801 (0.65 x 300 mm) Transgenomic, P/N ICE-99-9754. The mobile phase is 10 mN H₂SO₄ at a flow rate of 0.8 mL/min. UV detection (λ = 205 nm) is used to quantitate formic acid and total unknowns; Refractive Index detection is used to

quantitate formaldehyde (sensitivity = 512 mv). Injection volume is 100 μ L and run time is 240 minutes.

Table 1

Sample	Polymer	Amendment	Treatment	HCOOH	HC(O)H	IC	Unknowns
Example 8	PEG-2000	0.15% Initiator	Nitrogen		300	1579	3387845
Example 8 P	PEG-2000		LS-1 UV		284	226	4089917
Example 8 T	PEG-2000		Autoclaved	56	247	1460	1600472
Example 8 PA	PEG-2000		autoclaved + LS-1 UV	319	165	234	3387845
Example 9	PEG-2000	0.38% Initiator	Nitrogen	ND	276	4019	1561001
Example 9 P	PEG-2000		LS-1 UV	ND	308	466	9413559
Example 9 T	PEG-2000		Autoclaved	156	272	3786	1625876
Example 9 PA	PEG-2000		autoclaved + LS-1 UV	219	217	442	8508847
Example 10	PEG-2000	Ascorbate Buffer	Nitrogen		291	4146	1759608
Example 10 P	PEG-2000		LS-1 UV		337	136	21333767
Example 10 T	PEG-2000		Autoclaved	51	301	3822	1451887
Example 10 PA	PEG-2000		autoclaved + LS-1 UV		250	380	19728127
Example 11	PEG-2000	Citrate Buffer	Nitrogen		317	3825	1799368
Example 11 P	PEG-2000		LS-1 UV		339	482	8699143
Example 11 T	PEG-2000		Autoclaved		339	3747	1425557
Example 11 PA	PEG-2000		autoclaved + LS-1 UV		290	554	8110747
Example 12	PEG-2000	Sorbitol	Nitrogen		299	3967	1679516
Example 12 P	PEG-2000		LS-1 UV		243	375	7442590
Example 12 T	PEG-2000		Autoclaved	188	228	3723	1421715
Example 12 PA	PEG-2000		autoclaved + LS-1 UV	240	193	432	7803607
Example 13	PEG-2000	TEMPO	Nitrogen		286	3586	1715501
Example 13 P	PEG-2000		LS-1 UV		306	466	9072232
Example 13 T	PEG-2000		Autoclaved		302	2885	1155402
Example 13 PA	PEG-2000		autoclaved + LS-1 UV	156	266	692	9481513

IC stands for Irgacure® initiator.

Table 1 shows results of ion-exchange chromatography of samples generated in Examples 11 – 16. All results expressed in parts-per-million ($\mu\text{g/mL}$). A blank entry means that the analyte concentration is below the detection limit (50 ppm for formic acid)

Table 2

Sample	Polymer	Amendment	Treatment	HCOOH	HC(O)H	Irgacure	Unknowns
Example 14	PEG-Urea	0.15% Irgacure	Nitrogen			989	626725
Example 14 P	PEG-Urea		LS-1 UV	78		202	1205303
Example 14 T	PEG-Urea		Autoclaved			1364	1021780
Example 14 PA	PEG-Urea		autoclaved + LS-1 UV	195		243	869404
Example 15	PEG-Urea	0.38% Irgacure	Nitrogen			2842	448187
Example 15 P	PEG-Urea		LS-1 UV			533	7932312
Example 15 T	PEG-Urea		Autoclaved			4690	475180
Example 15 PA	PEG-Urea		autoclaved + LS-1 UV	136		868	7232686
Example 16	PEG-Urea	Ascorbate Buffer	Nitrogen			3593	697009
Example 16 P	PEG-Urea		LS-1 UV	69		165	21371459
Example 16 T	PEG-Urea		Autoclaved			4235	799883
Example 16 PA	PEG-Urea		autoclaved + LS-1 UV	60		380	16135664
Example 17	PEG-Urea	Citrate Buffer	Nitrogen			3170	535949
Example 17 P	PEG-Urea		LS-1 UV			662	7178992
Example 17 T	PEG-Urea		Autoclaved			3919	669291
Example 17 PA	PEG-Urea		autoclaved + LS-1 UV	74		521	5752951
Example 18	PEG-Urea	Sorbitol	Nitrogen			3238	614870
Example 18 P	PEG-Urea		LS-1 UV			746	7979709
Example 18 T	PEG-Urea		Autoclaved			4499	629794
Example 18 PA	PEG-Urea		autoclaved + LS-1 UV	124		551	5327765
Example 19	PEG-Urea	TEMPO	Nitrogen			3178	499934
Example 19 P	PEG-Urea		LS-1 UV			439	4215228
Example 19 T	PEG-Urea		Autoclaved			5232	504369
Example 19 PA	PEG-Urea		autoclaved + LS-1 UV	104		595	5215616

Table 2 shows results of ion-exchange chromatography of samples generated in Examples 14 – 19. All results expressed in parts-per-million ($\mu\text{g/mL}$). A blank entry means that the analyte concentration is below the detection limit.

As can be seen from the tables, the levels of formic acid in the irradiated and autoclaved samples are highest for any given family of samples. Furthermore, a second by-product of degradation, formaldehyde, is present in PEG materials of Examples 8-13, whereas formaldehyde is not detected in any PEG-urea polymers in Examples 14-19 (Table 2). The nature of the amendment added to the formulation has dramatic effects on by-product generation during the curing/autoclaving steps. As can be seen, sorbitol, whose hydroxyl groups should act as chain transfer agents, had very little efficacy as a stabilizer. The free-radical scavenger TEMPO has a modest effect on lowering the amount of detectable by-products, reducing them by approximately 25%. But the ascorbate and citrate buffered formulations have little or no detectable formic acid in any of the samples, indicating a large stabilizing effect brought by these materials. The efficacy of these two stabilizers versus the more conventional stabilizers sorbitol and TEMPO is unexpected.

There is a difference between the two buffers in terms of side effects. This is conveniently quantified by monitoring the “total unknowns” in the chromatograms. These unknowns have been partially characterized in that they are known to represent Irgacure decomposition products, high-molecular weight fragments of degraded polymer, and the like. In general, non-irradiated samples have total unknowns on the order of 2×10^6 counts; on irradiation, the unknowns increase to about 9×10^6 counts. Citrate-buffered PEG follows this trend with 1.8×10^6 counts before irradiation and 8.7×10^6 counts after irradiation and autoclave. Ascorbate buffered polyethylene glycol, however, shows an unknowns level of 1.8×10^6 counts before irradiation and 21.3×10^6 counts after, a ten-fold increase. All of the trends observed for the PEG were observed for the PEG Urea. There is thus a large and unexpected stabilization of PEG and PEG-Urea in the presence of an organic multi-acid of the present invention.

Example 20

2.45 g of Pyruvic Acid Sodium Salt (Aldrich) are diluted with 100 g of water. The pH of this solution is adjusted to 7.2 by addition of 15% aqueous sodium hydroxide. 0.5 g of Irgacure®-2959 is dissolved in 49.5 g of this mixture. 5.00 g of polymer from Example 1 is mixed with

- 30 -

0.75 g of this initiator solution and diluted to 6.00 g with water to afford a PEG-Urea/Irgacure® mixture amended with pyruvate.

Example 21

3.75 g of 2-Ketoglutaric Acid Monosodium Salt (Aldrich) are dissolved in 100 g of water. The pH of this solution is adjusted to 7.2 by addition of 15% aqueous sodium hydroxide. 0.5 g of Irgacure®-2959 is dissolved in 49.5 g of this mixture. 5.00 g of polymer from Example 1 is mixed with 0.75g of this initiator solution and diluted to 6.00 g with water to afford a PEG-Urea/Irgacure® mixture amended with 2-ketoglutarate.

Example 22

2.99 g of Malic Acid (Aldrich) are dissolved in 100 g of water. 2.99 g of Malic Acid Disodium Salt (Aldrich) are diluted to 100 g with water. The pH of this Malic Acid Disodium Salt solution is adjusted to 7.2 by addition of a small amount of the Malic Acid solution. 0.5 g of Irgacure®-2959 is dissolved in 49.5 g of this mixture. 5.00 g of polymer from Example 1 is mixed with 0.75 g of this initiator solution and diluted to 6.00 g with water to afford a PEG-Urea/Irgacure® mixture amended with malate buffer.

Samples of the above Examples 20, 21, and 22 are subjected to 25-minute exposure to UV light, followed by autoclave at 121 °C/30 minutes. UV light exposure is accomplished using a Macam Lamp with a Phillips HPA 400/30 S Sunlamp bulb directed by an EFOS® Liquid Light Guide and focused on a cylindrical cell quartz cuvette as described above. Lamp intensity is ca. 1.8 mW/cm², and exposure time is 25 minutes, implying exposure dose of 2.7 J/cm².

The samples are subjected to Ion Exchange Chromatography with the following results:

Sample	Treatment	HCOOH	HC(O)H	Irgacure	Unknowns
Example 20	Pyruvate	200		115	4481172
Example 21	Ketoglutarate			286	2567220
Example 22	Malate			187	713127

A blank entry in the above table means that the analyte concentration is below detection limits. It can thus be seen from the above examples that α -oxo-diacids have unexpected,

- 31 -

beneficial results in regard to PEG stabilization which are not realized in the case of the an α -oxo monoacid.

Example 23

74.26 g of Jeffamine XTJ-501 (from Huntsman Corporation), and 3.1 g of diethylene triamine (Aldrich Chemicals) are weighed into a jacketed 1-L reactor. 450 g of tetrahydrofuran (Aldrich) and 250 g of deionized water are added to the reactor and the contents are stirred to dissolve. The reactor is then chilled to 0 °C with stirring under nitrogen. 23.34 g of isophorone diisocyanate (Aldrich Chemicals, used as received) is then dissolved in 50 g of THF and added dropwise over 45 minutes. The solution is stirred at room temperature for one hour. 20 g of 20 % aqueous Sodium Carbonate (Aldrich) are added to the reactor and stirred to mix. 2.8 g of acryloyl chloride (Aldrich Chemicals, used as received) is then added in one portion, and the reactor is stirred at 0 °C for 30 minutes. Treatment of the reaction mixture with 20 g 20 % sodium carbonate, followed by 2.8 g of acryloyl chloride, is repeated twice more at 30 minute intervals. The product is then decanted to a 2-L flask, and the reactor is chased with 400 mL of water. The mixture is filtered with a 40 μ m sintered glass filter. The product is then concentrated on a rotary evaporator at 53°C/80 mBar ultimate vacuum to yield a solution essentially free of tetrahydrofuran. This solution is then ultrafiltered with 10 L of water using a 1-kilodalton membrane. The resulting purified solution is then concentrated to 25.33 % solids on a rotary evaporator.

Example 24

11.76 g of Sodium Citrate Dihydrate (Aldrich) is diluted to 1.0L with water in a volumetric flask. 0.8564 g of Sodium Dihydrogencitrate (Aldrich) is diluted to 100 mL with water in a 100 mL volumetric. Both solutions are thus 40 mM of citrate. The Sodium Citrate Dihydrate solution is pH-adjusted to 7.2 by adding the Sodium Dihydrogencitrate solution. 8.2 g of sodium chloride is then weighed into a 1-L volumetric and diluted to the mark with the citrate buffer.

Example 25

4.76 g of Disodium Phosphate (Aldrich), 0.77 g of Sodium Phosphate (Aldrich), and 8.2 g of sodium chloride are weighed into a 1-L volumetric and diluted to the mark with water.

Example 26

47.37 g of the 25.33% solids solution of Example 23 are weighed into a rotary evaporator flask. 19.77 g of water were removed at 55 °C/70 – 100 mBar. 2.4 g of initiator solution from Example 7 are added and the mixture is agitated to homogenize.

Example 27

44 mg of the material afforded by Example 26 is dosed into a quartz mold and the mold is closed. The mold is then exposed to UV light using a Macam Lamp with a Phillips HPA 400/30 S Sunlamp bulb. The output of the lamp is captured by an EFOS® Liquid Light Guide and focused into the mold. The intensity of the lamp is 1.85 mW/cm² and the exposure time is 20 s, implying an exposure energy of 37 mJ/cm². The molds are opened and the resulting contact lens is rinsed off. Five lenses are made in this way and placed in autoclave vials which contain 2.5 mL of the buffered saline of Example 24. The lenses are then subjected to 5 autoclave cycles (121 °C/30 minutes). The salines are then combined and analyzed by ion-exclusion chromatography. The saline is found to have 9 ppm of formic acid, a value below the Occupational Safety and Health Administration's Short-Term Exposure Limit (STEL) of 10 ppm.

Example 28

44 mg of the material afforded by Example 26 is dosed into a quartz mold and the mold is closed. The mold is then exposed to UV light using a Macam Lamp with a Phillips HPA 400/30 S Sunlamp bulb. The output of the lamp is captured by an EFOS® Liquid Light Guide and focused into the mold. The intensity of the lamp is 1.85 mW/cm² and the exposure time is 20 s, implying an exposure energy of 37 mJ/cm². The molds are opened and the resulting contact lens is rinsed off.

Five lenses made in this way are placed in autoclave vials which contains 2.5 mL of the buffered saline of Example 25. The lenses are then subjected to 5 autoclave cycles (121 °C/30 minutes). The salines are then combined and analyzed by ion-exclusion chromatography. The saline is found to have 36 ppm of formic acid. This value is well above the Occupational Safety and Health Administration's Short-Term Exposure Limit (STEL) of 10 ppm, rendering the lenses unfit for use.

The utility of the organic multi-acids of the present invention is thus unexpectedly equivalent regardless of where in the processing the organic multi-acids is employed.

EPO - DG 1


- 40 -

11. 08. 2004

Amended claims:

(93)

1. An ophthalmic device comprising: a poly(oxyalkylene)-containing polymeric material and a biocompatible organic multi-acid or biocompatible salt thereof, wherein the salt of the multi-acid is selected from the group consisting of sodium, potassium and ammonium salts, wherein the poly(oxyalkylene)-containing polymeric material has a polymer network having at least one unit of formula (I)



wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_4 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100; wherein the biocompatible organic multi-acid or biocompatible salt thereof is distributed within the poly(oxyalkylene)-containing polymeric material but not crosslinked to the polymer network, and wherein the biocompatible organic multi-acid or biocompatible salt thereof is present in an amount effective to improve the stability of the ophthalmic device so that the ophthalmic device has a decreased susceptibility to oxidative degradation, characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

2. The ophthalmic device of claim 1, wherein the biocompatible organic multi-acid is selected from the group consisting of hydroxy diacids, hydroxy triacids, and amino acids.

3. The ophthalmic device of claim 2, wherein the biocompatible organic multi-acid is an α -oxo-multi-acid.

4. The ophthalmic device of claim 3, wherein the α -oxo-multi-acid is selected from the group consisting of citric acid, 2-ketoglutaric acid, and malic acid.

5. The ophthalmic device of claim 4, wherein the ophthalmic device of the invention is a copolymerization product of a composition comprising (a) a prepolymer containing ethylenically unsaturated groups and at least one poly(oxyalkylene) unit of formula (I); (b) a water-soluble and biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of a poly(oxyalkylene)-containing polymeric material

- 41 -

made from the composition; (c) optionally a photoinitiator or a thermal initiator; and (d) optionally one or more vinylic monomers.


6. The ophthalmic device of claim 5, wherein the prepolymer is a crosslinkable polyurea.

7. The ophthalmic device of claim 56, wherein the prepolymer is a crosslinkable polyurethane.

8. The ophthalmic device of claim 4, wherein the biocompatible organic multi-acid or biocompatible salt thereof is impregnated within the poly(oxyalkylene)-containing polymeric material, wherein the poly(oxyalkylene)-containing polymeric material is a polymerization product of a reactive mixture comprising (a) a monomer or prepolymer having at least one poly(oxyalkylene) unit of formula (I) and functional groups which are amino, hydroxyl or isocyanato groups, and (b) an organic diamine, an organic polyamine, an organic diol, an organic polyol, an organic diisocyanate, or organic polyisocyanate, provided that components (a) and (b) react with each other to form a polyurea and/or polyurethane network.

9. A method for producing an ophthalmic device, comprising the steps of:

(1) obtaining a polymerizable fluid composition comprising (a) a prepolymer having ethylenically unsaturated groups and at least one poly(oxyalkylene) unit of formula (I)



wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_4 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100, (b) a biocompatible organic multi-acid or biocompatible salt thereof, wherein the salt of the multi-acid is selected from the group consisting of sodium, potassium and ammonium salts,

(c) optionally a photoinitiator or a thermal initiator, and (d) optionally one or more vinylic monomers;

(2) introducing an amount of the polymerizable fluid composition in a mold for making the ophthalmic device; and

(3) actinically or thermally polymerizing the polymerizable fluid composition in the mold to form the ophthalmic device having a polymer network having at least one unit of formula (I) and the biocompatible organic multi-acid or biocompatible salt thereof which is not crosslinked to the polymer network, wherein the biocompatible organic multi-acid or

- 42 -

biocompatible salt thereof is present in an amount effective to improve the stability of the ophthalmic device so that the ophthalmic device has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

10. The method of claim 9, wherein the biocompatible organic multi-acid is selected from the group consisting of hydroxy diacids, hydroxy triacids, olefinic diacids, olefinic tri-acids, and amino acids.

11. The method of claim 10, wherein the biocompatible organic multi-acid is an α -oxo-multi-acid.

12. The method of claim 11, wherein the α -oxo-multi-acid is selected from the group consisting of citric acid, 2-ketoglutaric acid, and malic acid.

13. The method of claim 11, wherein the prepolymer is a crosslinkable polyurea.

14. The method of claim 11, wherein the prepolymer is a crosslinkable polyurethane.

15. The method of claim 12, further comprising the steps of removing the ophthalmic device from the mold and hydrating the ophthalmic device in an aqueous solution containing the α -oxo-multi-acid or biocompatible salt thereof.

16. The method of claim 15, wherein the aqueous solution has an osmolarity of about 200 to 450 milli-osmole in 1000 ml (unit: mOsm/ml).

17. The method of claim 11, further comprising a step of sterilizing the ophthalmic device in an aqueous solution containing the α -oxo-multi-acid or biocompatible salt thereof.


18. The method of claim 17, wherein the aqueous solution has an osmolarity of about 200 to 450 milli-osmole in 1000 ml (unit: mOsm/ml).

19. A method for producing an ophthalmic device, comprising the steps of:

- 43 -

(1) introducing a reactive mixture into a mold by using a Reaction Injection Molding (RIM) process to form the ophthalmic device, wherein the reactive mixture comprises

(a) a monomer or prepolymer having functional groups and at least one poly(oxyalkylene) unit of formula (I)



in which R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_4 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100, wherein the functional groups are amino, carboxy, hydroxy or isocyanato groups, and

(b) an organic diamine, an organic polyamine, an organic diacid, an organic polyacid, an organic diol, an organic polyol, an organic diisocyanate, or organic polyisocyanate, provided that components (a) and (b) react with each other to form a polyurea and/or polyurethane network;

(2) removing the ophthalmic device from the mold; and

(3) impregnating the ophthalmic device with a biocompatible organic multi-acid or biocompatible salt thereof,

wherein the salt of the multi-acid is selected from the group consisting of sodium, potassium and ammonium salts,

and wherein the amount of the organic multi-acid or biocompatible salt thereof is effective to improve the stability of the ophthalmic device so that the ophthalmic device has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

20. The method of claim 19, wherein the biocompatible organic multi-acid is an α -oxo-multi-acid.


21. The method of claim 19, wherein the impregnating step is achieved by immersing the ophthalmic device for a period of time in an aqueous solution containing the α -oxo-multi-acid or biocompatible salt thereof.

22. The method of claim 19, wherein the reactive mixture further comprises one or more prepolymers having ethylenically unsaturated groups or one or more vinylic monomers to form a different polymer network which interpenetrates the polyurea and/or polyurethane network.

- 44 -

23. A stabilized poly(oxyalkylene)-containing polymeric material, which is a copolymerization product of a composition comprising:

(a) a prepolymer containing ethylenically unsaturated groups and at least one unit of formula



wherein R_1 , R_2 , and R_3 , independently of one other, are each linear or branched C_2 - C_6 -alkylene, and n , m and p , independently of one another, are each a number from 0 to 100, wherein the sum of $(n+m+p)$ is 5 to 100; and

(b) a biocompatible organic α -oxo-multi-acid or biocompatible salt thereof,

wherein the salt of the α -oxo-multi-acid is selected from the group consisting of sodium, potassium and ammonium salts,

wherein the organic multi-acid or biocompatible salt thereof is present in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymeric material, so that the polymeric material has a decreased susceptibility to oxidative degradation characterized by having at least an 1.5-fold reduction of the amount of detectable formic acid and optionally other degradation by-products.

and wherein the multi-acid or salt thereof is distributed within the polymeric material but not crosslinked to the polymer network.

24. The stabilized poly(oxyalkylene)-containing polymeric material of claim 23, wherein the prepolymer in step (a) additionally comprises one or more vinylic monomers.

25. The stabilized poly(oxyalkylene)-containing polymeric material of claim 23 or 24, wherein the α -oxo-multi-acid is selected from the group consisting of citric acid, 2-ketoglutaric acid, and malic acid.